Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wave Life SciencesWVE +3.29%60 3-Year EBITDA Growth Rate is 14.10% as of Jun. 2026, which is 86% above its 10-year median of 7.60. GuruFocus rates WVE with a GF Score™ of 60/100 and a GF Value™ of $3.89 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,127 Biotechnology companies, Wave Life Sciences ranks worse than 50.84% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 25.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Wave Life Sciences was 46.70% per year. The lowest was -149.30% per year. And the median was 7.60% per year.
Wave Life Sciences (NAS:WVE) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Wave Life Sciences 3-Year EBITDA Growth Rate Related Terms
WVE vs IMMX, CADL, ARDX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Wave Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wave Life Sciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wave Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Wave Life Sciences's 3-Year EBITDA Growth Rate falls into.
Wave Life Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.10% mean?
Wave Life Sciences (WVE) has a 3-Year EBITDA Growth Rate of 14.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Wave Life Sciences and its competitors. This is 86% above median its historical median of 7.60. According to the industry distribution chart, Wave Life Sciences ranks #573 out of 1127 companies in the Biotechnology industry, placing it in the top 50.8%.
Is Wave Life Sciences' 3-Year EBITDA Growth Rate too high?
Wave Life Sciences' current 3-Year EBITDA Growth Rate of 14.10% is 86% above median its 10-year median of 7.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Wave Life Sciences' value of 14.10% is 3.4% below this industry median. Based on the distribution chart, Wave Life Sciences ranks #573 out of 1127 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Wave Life Sciences has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' 3-Year EBITDA Growth Rate compare to IMMX and CADL?
According to the Biotechnology industry distribution chart, Wave Life Sciences ranks #573 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Wave Life Sciences in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Wave Life Sciences' value of 14.10% is 3.4% below this benchmark. While the company's 10-year median is 7.60 vs. the industry median of 14.60, Wave Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wave Life Sciences's current 3-Year EBITDA Growth Rate of 14.10% is 3.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Wave Life Sciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wave Life Sciences's current 3-Year EBITDA Growth Rate is 14.10%, which is 86% above median its own 10-year median of 7.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.89, compared to a current price of $4.85 — trading 24.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.10%, which is 86% above median its 10-year median of 7.60 and 3.4% below the Biotechnology industry median of 14.60. Wave Life Sciences' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current 3-Year EBITDA Growth Rate is 14.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wave Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued.
The current stock price of $4.85 is trading 24.7% above its estimated GF Value™ of $3.89.
GuruFocus considers Wave Life Sciences to be Modestly Overvalued.
Key valuation signals for WVE:
3-Year EBITDA Growth Rate: 14.10% (86% above median its 10-year median of 7.60)
GF Value™: $3.89 vs. price of $4.85 (24.7% above fair value)
Industry Position: 3.4% below the Biotechnology median (#573 of 1127)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
60GF Score
Get the complete analysis for WVE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
